Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

TARS

NASDAQ

Tarsus Pharmaceuticals (TARS)

67.55 USD −2.20% vs prior close Nov 5, 2026
Tarsus Pharmaceuticals, Inc. price graph
53 sessions
100 60 24 Aug 5 Nov

The line runs 72.82 USD on 24 August through 67.55 USD on 5 November, on a scale from 60 to 100. Days the market did not trade hold the previous close, flat.

Market cap
3.3B USD
Revenue, year to Dec 2025
451.4M USD
EPS, diluted, year to Dec 2025
−1.59 USD
52-week range
56 USD – 90.81 USD
Avg volume
49.5K

as of Nov 5, 2026

Have Tarsus Pharmaceuticals (TARS) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Tarsus Pharmaceuticals insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Dec 2025, show no open-market purchase.

Form 4, 90 days to 22 Nov 2026, newest reported trade 13 Nov 2026

0buys
8sells
$6.00Mnet sold
3other filings
Have Tarsus Pharmaceuticals (TARS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
13 Nov 2026Azamian Bobak R.President/CEO and Board ChairSell10,000803K USD
15 Sep 2026LINK WILLIAM J PHDDirectorSell12,500980K USD
04 Sep 2026Azamian Bobak R.President/CEO and Board ChairSell10,000906K USD
04 Sep 2026Lin Elizabeth YeuChief Medical OfficerSell13,9531.2M USD
04 Sep 2026Neervannan SeshadriChief Operating OfficerSell4,564388K USD
02 Sep 2026Azamian Bobak R.President/CEO and Board ChairSell10,000801K USD
02 Sep 2026Lin Elizabeth YeuChief Medical OfficerSell6,977558K USD
01 Sep 2026Lin Elizabeth YeuChief Medical OfficerSell4,601340K USD
Sold8 open-market sales72,595$6.00M
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Tarsus Pharmaceuticals (TARS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Sep 2026LINK WILLIAM J PHDDirectorOption exercise201
15 Sep 2026PYOTT DAVID E IDirectorOption exercise201
15 Sep 2026YARNO WENDY LDirectorOption exercise302

Which funds hold Tarsus Pharmaceuticals (TARS)?

9 of the 45 institutional funds we track reported a Tarsus Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 220.4M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Tarsus Pharmaceuticals (TARS)?
FundPositionSharesValueShares q/q
Millennium ManagementHeld (±25%)1,093,86885.5M USD−23.4%
Balyasny Asset ManagementNew position616,40448.5M USD
D. E. Shaw & Co.Trimmed465,02536.6M USD−34.6%
Two Sigma InvestmentsAdded183,66514.4M USD+409.6%
Marshall WaceNew position148,54711.7M USD
Citadel AdvisorsTrimmed109,1708.2M USD−54.8%
Point72 Asset ManagementNew position85,0006.7M USD
Renaissance TechnologiesAdded72,1005.7M USD+675.3%
AQR Capital ManagementHeld (±25%)39,9913.1M USD−4.8%
Tudor Investment CorpExited

What has been filed or recorded for Tarsus Pharmaceuticals (TARS)?

The filings we hold for Tarsus Pharmaceuticals, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Tarsus Pharmaceuticals (TARS)?
And
30 Oct 2026Fails to deliverShares failed to deliver17,567 shares1.3M USD notional · 0.036% of shares out
29 Oct 2026Fails to deliverShares failed to deliver896 shares65K USD notional · 0.002% of shares out
23 Oct 2026Fails to deliverShares failed to deliver86 shares6K USD notional · <0.001% of shares out
16 Oct 2026Fails to deliverShares failed to deliver22,500 shares1.6M USD notional · 0.046% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −14.40 USDRevenue $195M
30 Sep 2026FinancialsTotal assets505.5M USDat period end
30 Sep 2026FinancialsTotal equity104.0M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.43 USDRevenue $174M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.16 USDRevenue $162M
31 Dec 2025Annual reportFY 2025 reportedEPS −1.59 USDRevenue $451M
31 Dec 2025FinancialsRevenue451.4M USDfiscal year
31 Dec 2025FinancialsNet income−66.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.59 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.30 USDRevenue $119M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.48 USDRevenue $103M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.64 USDRevenue $78M
31 Dec 2024Annual reportFY 2024 reportedEPS −3.07 USDRevenue $183M

What do people ask about Tarsus Pharmaceuticals (TARS)?

From live data
What did Tarsus Pharmaceuticals shares close at?67.55

Tarsus Pharmaceuticals closed at 67.55 USD on 5 Nov 2026, down 2.20% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Tarsus Pharmaceuticals’ market cap?3.3B

Tarsus Pharmaceuticals is worth 3.3B USD by market value as of 5 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Tarsus Pharmaceuticals’ revenue?451.4M

Tarsus Pharmaceuticals reported revenue of 451.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Tarsus Pharmaceuticals insiders bought or sold shares recently?8 sales

In the 90 days to 22 Nov 2026, Tarsus Pharmaceuticals insiders reported 8 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 4 Dec 2025, show no open-market purchase. A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Tarsus Pharmaceuticals?9 of 45

9 of the 45 funds we track reported a Tarsus Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Balyasny Asset Management and D. E. Shaw & Co. See Funds

When did Tarsus Pharmaceuticals last report earnings?−14.40

Tarsus Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −14.40 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words